Rostgaard, Nina
Olsen, Markus Harboe
Ottenheijm, Maud
Drici, Lylia
Simonsen, Anja Hviid
Plomgaard, Peter
Gredal, Hanne
Poulsen, Helle Harding
Zetterberg, Henrik
Blennow, Kaj
Hasselbalch, Steen Gregers
MacAulay, Nanna
Juhler, Marianne
Funding for this research was provided by:
Novo Nordisk Fonden (NNF17OC0024718)
Novo Nordisk Fonden,Denmark (NNF19OC0055001)
Absalonfonden
Swedish Research Counsil (#2018-02532)
European Research Council (#681712)
European Research Council,European Union (#101053962)
Swedish State Support for Clinical Research (#ALFGBG-71320)
Alzheimer's Drug Discovery Foundation (#201809-2016862)
AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C)
Olav Thon Stiftelsen
Familjen Erling-Perssons Stiftelse
Stiftelsen för Gamla Tjänarinnor
Hjärnfonden (#FO2019-0228)
European Union’s Horizon 2020 research and innovation programme (No 860197 (MIRIADE))
European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute at UCL (UKDRI-1003)
Article History
Received: 9 September 2022
Accepted: 29 December 2022
First Online: 21 January 2023
Declarations
:
: Written informed consent was obtained from all patients and the study was approved by the Ethical committee of the Capital Region of Denmark (H-19001474 and H-18046630). All animal experiments were performed according to the legislation for animal protection and care, animal permission no. 2016-15-0201-00957 approved by the Danish Animal Experiments Inspectorate and the Local Ethics Committee at The Department of Veterinary Clinical Sciences, University of Copenhagen. All animals were euthanized upon CSF collection.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare that they have no competing interests.